CRISPR THERAPEUTICS AG
NASDAQ: CRSP (CRISPR Therapeutics AG)
Last update: yesterday, 3:49PM50.23
0.94 (1.91%)
| Previous Close | 49.29 |
| Open | 48.30 |
| Volume | 2,020,350 |
| Avg. Volume (3M) | 2,484,060 |
| Market Cap | 4,786,930,688 |
| Price / Earnings (Forward) | 23.36 |
| Price / Sales | 126.77 |
| Price / Book | 2.52 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -17,158.84% |
| Diluted EPS (TTM) | -4.49 |
| Quarterly Revenue Growth (YOY) | 71.60% |
| Total Debt/Equity (MRQ) | 11.99% |
| Current Ratio (MRQ) | 15.64 |
| Operating Cash Flow (TTM) | -306.47 M |
| Levered Free Cash Flow (TTM) | -193.24 M |
| Return on Assets (TTM) | -12.88% |
| Return on Equity (TTM) | -19.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CRISPR Therapeutics AG | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -1.13 |
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 76.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sr One Capital Management, Lp | 30 Sep 2025 | 2,038,763 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 1,389,276 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 93.00 (B of A Securities, 85.15%) | Buy |
| Median | 77.00 (53.30%) | |
| Low | 44.00 (Baird, -12.40%) | Hold |
| Average | 70.57 (40.49%) | |
| Total | 5 Buy, 2 Hold | |
| Avg. Price @ Call | 58.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 12 Nov 2025 | 77.00 (53.29%) | Buy | 52.19 |
| Baird | 11 Nov 2025 | 44.00 (-12.40%) | Hold | 55.21 |
| RBC Capital | 11 Nov 2025 | 50.00 (-0.46%) | Hold | 55.21 |
| Needham | 10 Nov 2025 | 80.00 (59.27%) | Buy | 54.58 |
| 10 Oct 2025 | 81.00 (61.26%) | Buy | 73.07 | |
| B of A Securities | 17 Oct 2025 | 93.00 (85.15%) | Buy | 69.15 |
| HC Wainwright & Co. | 23 Sep 2025 | 80.00 (59.27%) | Buy | 60.76 |
| JP Morgan | 18 Sep 2025 | 70.00 (39.36%) | Buy | 62.94 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |